dromlakhani Use short-acting octreotide as needed until conception
STEP 1 — Gather Information
Confirm diagnosis of acromegaly, current long-acting SRL (octreotide LAR or lanreotide autogel) or pegvisomant therapy, and pregnancy intention; assess timing for discontinuation (~2 months before conception attempt), baseline symptoms, tumor size, and IGF-1 levels to determine need for ongoing disease control.
STEP 2 — Rule In / Rule Out
If the patient has asymptomatic disease with low tumor burden and normal IGF-1, consider holding all therapy; if symptomatic, progressive tumor growth, or elevated IGF-1 indicating need for control, proceed to short-acting octreotide.
STEP 3 — Classify or Stratify
For patients requiring therapy, prescribe short-acting octreotide 50–100 mcg subcutaneously every 6–8 hours as needed for symptoms or biochemical control, adjusting based on headache, IGF-1 trends, and tumor-related signs.
STEP 4 — Decide
Continue short-acting octreotide until a positive pregnancy test confirms conception, then discontinue all medical therapy except for tumor- or headache-related indications per pregnancy guidance.
Clinical Guardrails / Mimics / Pitfalls
Do not use long-acting SRL or pegvisomant during pregnancy due to placental transfer and limited safety data; avoid relying on GH/IGF-1 monitoring in pregnancy as placental GH confounds assays; monitor for hypoglycemia and injection-site reactions; use the lowest effective dose and assess tumor growth clinically (headaches, visual fields) rather than biochemical markers.
Concrete Clinical Example
A 32-year-old woman on octreotide LAR 30 mg monthly plans pregnancy; she discontinues LAR 2 months before attempting conception, develops mild headaches and elevated IGF-1, starts short-acting octreotide 50 mcg SC TID PRN, continues until pregnancy test positive, then stops therapy and undergoes serial visual field monitoring for tumor growth.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Katznelson et al., 2014, doi:10.1210/jc.2014-2700